drugset / Trial / NCT04379999
Atorvastatin ± Aspirin in Lynch Syndrome Syndrome
Non-randomizedParallel-groupOpen-labelPrevention
Summary
The goal of this study is to investigate that a common cholesterol lowering agent (atorvastatin) alone or combining with a nonsteroidal anti-inflammatory drug (aspirin) would reduce the risk of colorectal cancer (CRC) in high-risk individuals with Lynch syndrome.
Timeline
- Start
- 2018-09-10
- Primary completion
- 2025-08-04
- Completion
- 2025-08-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aspirin | Small molecule | 325 mg | — |
| Comparator | Atorvastatin | Small molecule | 20 mg | — |